Omeros’ (OMER) “Buy” Rating Reiterated at HC Wainwright

Omeros (NASDAQ:OMER)‘s stock had its “buy” rating reiterated by HC Wainwright in a report released on Thursday,Benzinga reports. They currently have a $40.00 target price on the biopharmaceutical company’s stock. HC Wainwright’s target price would indicate a potential upside of 178.16% from the stock’s previous close.

A number of other research analysts also recently weighed in on the company. D. Boral Capital reissued a “buy” rating and issued a $36.00 price objective on shares of Omeros in a research note on Tuesday, April 21st. Zacks Research raised Omeros from a “hold” rating to a “strong-buy” rating in a research note on Thursday, April 2nd. Wall Street Zen downgraded Omeros from a “buy” rating to a “hold” rating in a research note on Sunday, April 26th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Omeros in a research note on Tuesday, April 21st. Two analysts have rated the stock with a Strong Buy rating, two have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $40.33.

Omeros Price Performance

OMER opened at $14.38 on Thursday. The business has a 50-day moving average of $12.22 and a 200-day moving average of $11.35. Omeros has a fifty-two week low of $2.95 and a fifty-two week high of $17.65. The company has a market capitalization of $1.04 billion, a PE ratio of -28.76 and a beta of 2.66.

Omeros (NASDAQ:OMER) last issued its quarterly earnings data on Wednesday, May 13th. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.16. The company had revenue of $9.89 million during the quarter, compared to the consensus estimate of $10.05 million. On average, equities research analysts expect that Omeros will post -1.54 earnings per share for the current fiscal year.

Institutional Trading of Omeros

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. International Assets Investment Management LLC grew its holdings in Omeros by 16.0% in the 1st quarter. International Assets Investment Management LLC now owns 5,800 shares of the biopharmaceutical company’s stock valued at $61,000 after buying an additional 800 shares during the last quarter. Farther Finance Advisors LLC grew its holdings in shares of Omeros by 16.5% during the 4th quarter. Farther Finance Advisors LLC now owns 7,106 shares of the biopharmaceutical company’s stock worth $122,000 after purchasing an additional 1,004 shares in the last quarter. State of Wyoming acquired a new stake in shares of Omeros during the 4th quarter worth approximately $25,000. AQR Capital Management LLC grew its holdings in shares of Omeros by 7.2% during the 4th quarter. AQR Capital Management LLC now owns 22,838 shares of the biopharmaceutical company’s stock worth $392,000 after purchasing an additional 1,532 shares in the last quarter. Finally, ProShare Advisors LLC grew its holdings in shares of Omeros by 12.1% during the 4th quarter. ProShare Advisors LLC now owns 15,171 shares of the biopharmaceutical company’s stock worth $261,000 after purchasing an additional 1,637 shares in the last quarter. Institutional investors and hedge funds own 48.79% of the company’s stock.

About Omeros

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.